LITTLE KNOWN FACTS ABOUT MIDOSTAURIN.

Hepatic impairment No dose adjustment is necessary in clients with delicate or reasonable (Youngster-Pugh A or B) hepatic impairment (see area 5.2). Exposure to midostaurin and its Lively metabolite CGP62221 is substantially lower in patients with significant hepatic impairment than that in individuals with normal hepatic operate (see part five.Doc